RSS-Feed abonnieren
DOI: 10.1055/s-0039-3403161
In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles
Publikationsverlauf
Publikationsdatum:
28. Februar 2020 (online)
This abstract will be presented at ERS 2019 in Madrid, Spain.
Thorsten Aldekamp is presenting this Encore on behalf of all authors with their permissions.
Introduction: When using a DPI, critical patient inhalation characteristics such as inspiratory flow rate and inhaled volume vary widely between individuals, disease state and severity.
Aim: This study aimed to evaluate the dose delivery performance of a triple combination DPI (Trelegy ELLIPTA) containing FF/UMEC/VI 100/62.5/25 µg, across the full range of inhalation characteristics relevant to patients with all severities of chronic obstructive pulmonary disease (COPD).
Method: Five representative pre-recorded patient inhalation profiles encompassing the full range of peak inspiratory flow rates (PIFRs) for patients of all COPD severities (Prime D, et al. J Aerosol Med Pulm Drug Deliv, 2015), were replicated using the EL breathing simulator with a coated anatomical throat model and Next Generation Impactor (Hamilton M, et al. J Aerosol Med Pulm Drug Deliv, 2015). Dose deposited within the throat and impactor stages were analysed to determine the delivered dose (DD) and fine particle dose (FPD, mass < 5 µm).
Results: Mean DD and FPD were consistent for FF, UMEC and VI ([Fig. 1]) across the full range of patient-relevant inhalation characteristics, including PIFR 43.5 to 129.9 L/min.
Conclusion: COPD patients, including those with very severe COPD, can achieve the inspiratory effort required for consistent dose delivery.
Conflicts of interest: DP, MH, ET are employees of, and hold shares in GlaxoSmithKline plc.
Funding: This study was funded by GlaxoSmithKline plc.
Trademarks are the property of their respective owners.
#